Wall Street brokerages expect T2 Biosystems, Inc. (NASDAQ:TTOO) to report ($0.43) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have issued estimates for T2 Biosystems’ earnings, with the lowest EPS estimate coming in at ($0.49) and the highest estimate coming in at ($0.39). T2 Biosystems reported earnings of ($0.47) per share during the same quarter last year, which indicates a positive year over year growth rate of 8.5%. The firm is expected to report its next earnings results on Thursday, February 15th.

On average, analysts expect that T2 Biosystems will report full year earnings of ($1.88) per share for the current fiscal year, with EPS estimates ranging from ($1.97) to ($1.81). For the next year, analysts expect that the firm will post earnings of ($1.68) per share, with EPS estimates ranging from ($1.97) to ($1.53). Zacks’ EPS calculations are an average based on a survey of research analysts that that provide coverage for T2 Biosystems.

T2 Biosystems (NASDAQ:TTOO) last announced its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.45) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.49) by $0.04. T2 Biosystems had a negative return on equity of 244.82% and a negative net margin of 1,497.70%. The company had revenue of $1.11 million during the quarter, compared to the consensus estimate of $1.10 million. The firm’s revenue was up 2.8% compared to the same quarter last year.

A number of research analysts have issued reports on TTOO shares. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of T2 Biosystems in a report on Friday, November 3rd. Canaccord Genuity reissued a “buy” rating and issued a $6.00 price target on shares of T2 Biosystems in a report on Monday, October 30th. ValuEngine upgraded T2 Biosystems from a “strong sell” rating to a “sell” rating in a research report on Wednesday, September 13th. Finally, Zacks Investment Research upgraded T2 Biosystems from a “sell” rating to a “hold” rating in a research report on Thursday, October 5th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $6.54.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. increased its position in shares of T2 Biosystems by 0.4% during the second quarter. Goldman Sachs Group Inc. now owns 4,270,632 shares of the medical equipment provider’s stock worth $13,709,000 after purchasing an additional 18,000 shares in the last quarter. Senvest Management LLC increased its position in shares of T2 Biosystems by 17.6% during the third quarter. Senvest Management LLC now owns 3,337,946 shares of the medical equipment provider’s stock worth $14,019,000 after purchasing an additional 500,000 shares in the last quarter. Lagoda Investment Management L.P. increased its position in shares of T2 Biosystems by 15.4% during the second quarter. Lagoda Investment Management L.P. now owns 1,975,921 shares of the medical equipment provider’s stock worth $6,343,000 after purchasing an additional 264,337 shares in the last quarter. Essex Investment Management Co. LLC increased its position in shares of T2 Biosystems by 239.2% during the third quarter. Essex Investment Management Co. LLC now owns 706,194 shares of the medical equipment provider’s stock worth $2,966,000 after purchasing an additional 498,004 shares in the last quarter. Finally, Susquehanna International Group LLP increased its position in shares of T2 Biosystems by 931.3% during the second quarter. Susquehanna International Group LLP now owns 85,620 shares of the medical equipment provider’s stock worth $275,000 after purchasing an additional 95,920 shares in the last quarter. Hedge funds and other institutional investors own 53.39% of the company’s stock.

Shares of T2 Biosystems (TTOO) traded down $0.18 during trading hours on Thursday, reaching $3.97. The company’s stock had a trading volume of 93,300 shares, compared to its average volume of 170,444. T2 Biosystems has a one year low of $2.50 and a one year high of $7.07. The company has a debt-to-equity ratio of 2.25, a current ratio of 5.40 and a quick ratio of 5.28.

WARNING: This article was first posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://www.watchlistnews.com/0-43-eps-expected-for-t2-biosystems-inc-ttoo-this-quarter/1703287.html.

T2 Biosystems Company Profile

T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).

Get a free copy of the Zacks research report on T2 Biosystems (TTOO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for T2 Biosystems (NASDAQ:TTOO)

Receive News & Ratings for T2 Biosystems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.